The effects of inhaled procaterol on COPD patients.

The effects of inhaled procaterol on COPD patients. - The effects of inhaled procaterol on COPD patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003174

Enrollment

Registered

2010-02-12

Start date

2010-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease (COPD)

Interventions

Inhalation of procaterol Inhalation of placebo.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Able and willing to read, understand, and provide written Informed Consent; 2.Age range of 30-80 years; FEV1%<70% after bronchodilator inhalation Diagnosed as COPD %FEV1<80% MRC dyspnea grade >=1 Chest CT within 6 months

Exclusion criteria

Exclusion criteria: History of exacerbation in the previous 8 weeks Co-morbid conditions (heart diseases or neuromuscular diseases) limiting exercise. The other significant conditions that seem to limit study protocol.

Design outcomes

Primary

Measure	Time frame
The collerations between clinical and functional parameters and the effects procaterol inhalation on lung function, dyapnea and exercise performance (6MW) in patients with COPD .	—

Secondary

Measure	Time frame
Adverse event	—

Countries

Japan

Contacts

Public ContactMasamichi Mineshita

St.Marianna University School of Medicine Respiratory and Infectious Diseases

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026